• Text version
• Text Size:   
• Small
• Medium
• Large
• Sitemap
• Languages
• Accessibility
• Contact

• Home
• Services
  • Advanced search
  • A to Z
• Service users
  • Service User Involvement
  • Education and employment
  • Service User Survey 2013
  • Carers
  • Advice and Complaints Service (was PALS)
  • Mental Health Law
    • Amendments to the Mental Health Act
    • Human rights act
    • MHA Rights Leaflets
    • Mental Capacity Act
    • Mental Health Act Managers
• Members
  • August 2012 Governor Elections
• News
  • News
    • News archive
  • Events
  • Recent changes to services
• Mental Health
  • Getting Help in an Emergency
  • Understanding Mental Health Conditions and Treatment
  • Medication
  • Mental wellbeing
    • Get Active
    • Towards a Smoke Free Life
• Research
  • Academic Health Science Centre
  • Local Research Networks and research support
    • DeNDRoN
    • Mental Health Research
    • Primary Care Research Network
    • NoCLoR
    • Research Design Service
  • Research and innovation
    • Putting research into practise
    • Studies and publications
  • Be involved
• Careers
• About Us
  • Board Members
    • Board Meetings
  • Governors
    • Governors Meetings
  • Independent Ratings
  • Annual Report and Annual Plan
  • Quality Accounts
  • Clinical Governance
  • Equality and Diversity
  • Infection control
  • Access to personal information
    • Legislative Background
    • Rights under data protection
    • Requesting information
    • Making a complaint
  • Safeguarding children
  • Safeguarding adults
  • Same-sex accommodation
  • Freedom of Information and Data Protection
    • Data protection and confidentiality
    • Publication Scheme
    • FOI Disclosure Log
  • Excellence in Camden & Islington

• Home
• Mental Health
• Medication

Medication

Trust formulary

Please click here for the Trust's medicines formulary.

NICE Medicines Guidance

The National Institute for Health and Clinical Excellence (NICE(external link)) advises the National Health Service (NHS) regarding treatments that should be made available. NICE issues this advice in several forms.

The most  well known of these are public health guidance(external link) that aims to prevent ill health, clinical guidelines(external link) which cover the treatment of individual conditions, and technology appraisals(external link) that describe the place in treatment of individual medicines or medical procedures. 

Camden & Islington NHS Foundation Trust has a responsibility to ensure that treatments recommended by NICE are made available to patients. The trust must also ensure any treatments that NICE recommend should not be used, are not used. 

Under the NHS Constitution(external link), patients have the right to receive medicines and treatments that are recommended in NICE technology appraisals if their doctor thinks that these treatments are right for them. When NICE recommends a treatment, the trust must make it available within 3 months of that recommendation. 

In a letter from the NHS chief executive Innovation, Health and Wealth, publication of NHS formularies(external link) PDF (new window) (2012), the Department of Health has stated that all NHS Organisations should publish information which sets out which NICE technology appraisals are included in their local formularies by April 1st  2013.

In Camden & Islington NHS Foundation Trust, the Drug and Therapeutics Group discusses new NICE medicines related technology appraisals and decides if they are relevant to the services that the trust provides. This group has agreed that the following technology appraisals related to the use of medicines are relevant to the services we are responsible for providing: 

TA77(external link) PDF (new window) Zaleplon, zolpidem and zopiclone for the short-term management of insomnia

TA98(external link) PDF (new window) Methylphenidate, atomoxetine, and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents.

TA114 (external Link) PDF (new window) Drug misuse - methadone and buprenorphine

TA115 (external Link) PDF (new window) Drug misuse - naltrexone

TA123 (external Link) PDF (new window) Varenicline for smoking cessation

TA213(external link) PDF (new window) Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

TA217(external link) PDF (new window) Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimers disease

The Drug and Therapeutics Group has made sure that the recommendations in these technology appraisals have been included in the trust's formulary and prescribing guidelines.  All recommended medicines have been made available for doctors to prescribe. 

The North Central London Joint Formulary Committee and the trust's Drug and Therapeutics Group are also responsible for deciding whether medicines that have not been assessed by NICE should be made available.